Low blood sugar levels (hypoglycemia) are a more serious risk linked to the GLP-1 class of drugs
These typically occur at 36 month intervals and include assessment of: Blood pressure and heart rate measurement Glycaemic control (HbA1c) Weight and body mass index Renal function Tolerability and adverse effects Patients with pre-existing cardiovascular conditions may require more frequent monitoring or specialist cardiology input

Start Free Assessment Table of contents Why 5mg vials come as powder instead of pre-mixed solution Materials checklist: what you need before starting The reconstitution math: choosing your concentration Step-by-step reconstitution protocol What most articles get wrong about mixing technique Visual inspection: what properly reconstituted semaglutide looks like The three failure modes of compounded reconstitution Post-reconstitution storage and stability Calculating your dose after reconstitution When to discard and start a new vial Common reconstitution errors and how to avoid them FAQ Why 5mg vials come as powder instead of pre-mixed solution Semaglutide is a 31-amino-acid peptide analog of human GLP-1
It appears as a white lyophilized powder that is soluble in water
Palatin Technologies has two additional MC4R agonists, PL-7737 which is an oral small molecule, and PL-8905 which is a synthetic peptide, both in preclinical development for obesity indications, with the former specifically targeting obesity caused by LEPR deficiency 15
O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al